238000003259 recombinant expression Methods 0.000 claims description 8.108020004707 nucleic acids Proteins 0.000 claims description 15.150000007523 nucleic acids Chemical class 0.000 claims description 16.229920002106 messenger RNA Polymers 0.000 claims description 16.108020004999 Messenger RNA Proteins 0.000 claims description 16.230000000694 effects Effects 0.000 claims abstract description 6.102100007156 SMN1 Human genes 0.000 claims abstract description 45.108090000623 proteins and genes Proteins 0.000 claims abstract description 50.102000004169 proteins and genes Human genes 0.000 claims abstract description 50.101700016511 SRSF1 Proteins 0.000 title claims abstract description 26.208000002320 Spinal Muscular Atrophy Diseases 0.000 title claims abstract description 30.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to EP15165741.8 priority Critical Priority to EP15165741.8A priority patent/EP3087995A1/en Application filed by Eth Zurich filed Critical Eth Zurich Publication of WO2016174123A1 publication Critical patent/WO2016174123A1/en Links Inventor Frédéric ALLAIN Antoine CLÉRY Original Assignee Eth Zurich Priority date (The priority date is an assumption and is not a legal conclusion.
Google Patents WO2016174123A1 - Mutants of srsf1 (asf/sf2) for treating spinal muscular atrophy WO2016174123A1 - Mutants of srsf1 (asf/sf2) for treating spinal muscular atrophy